| BACKGROUNDIschemia is a common disease threatening human's health with its high morbility, mortality and mutilation rate. Studies on the mechanisms of acute cerebral ischemia have been carrying on for several decades, but the status of patients' prognosis still did not improved satisfactorily. Interruption of blood supply causes ischemia, which rapidly damages metabolically active tissues. Paradoxically, restoration of blood flow to the ischemic tissues initiates a cascade of pathology that leads to additional cell or tissue injury, which is called ischemia/reperfusion (I/R) injury. Oxygen free radicals or oxidants have been proposed to be involved in acute central nervous system injury that is produced by cerebral ischemia and reperfusion. So scavenging free radicals is one of the major targets of treatment with I/R injury. Recently, edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186) ), a potent free radical scavenger, has been successfully applied in treatment of patients with acute cerebral ischemia. Previous studies showed that edaravone would have neuroprotective effects on an acute model of cerebral ischemia possibly via its free radical scavenging and antioxidant actions. Futhermore, a recent randomized, double-blind, placebo controlled clinical trial has demonstrated neuroprotective effects of edaravone in patients with acute cerebral infraction. However, these studies focus on the measure of ischemia volume, observation of symptoms and physical signs in animal models and acute ischemia patients. To our knowledge,... |
PDF Full Text Request